NeuroSense Therapeutics Ltd. (NRSNW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Medinat ha-Yehudim Street 85
Herzliya, 4676670
Israel
Phone
972 9 953 1142
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
December 09, 2021
| Name | Title | Pay | Year Born |
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | 392,000 | 1979 |
| Niva Russek-Blum | Chief Technology Officer | 201,000 | 1979 |
| Or Eisenberg | Chief Financial Officer | 273,000 | 1981 |
| Ferenc Tracik | Chief Medical Officer | 447,000 | 1964 |
| Yael Barak | Vice President of Quality & Compliance | 0 | 1970 |
| Keren Pushett | Head of HR | 0 | N/A |
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.